In fact, in BRCA mutated population, a level of HE4 higher than 65,6pmol/L after the third cycle of chemotherapy seems to be an effective prognostic marker to identify those patients who will develop an ovarian cancer relapse (sensitivity = 75; specificity= 99; AUC = 92%, p value < 0.001; LR+ = 750; Post-test probability = 99%) (Table 5). The gene discussed is WFDC2; the disease is ovarian carcinoma.